Under construction – not a live service
Sign in
CompletedNo phase

Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)

Key facts

Who runs it
DePuy Orthopaedics
Where
Boston, Columbus, Denver, Durham, Louisville, Philadelphia, Sacramento, and Tampa, United StatesSee the 9 sitesAlso in 1 other country, 4 sites
Trial code
Status
Completed
People taking part
172 people enrolled
Started
1 Jun 2014
Ended
31 Dec 2023
Type of study
Interventional
Treatments tested
  • COC 36mm
Record updated
16 July 2025

Who can take part

Age
21 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Males and females between 21 - 75 at the time of surgery
  • Individuals, who in the opinion of the investigator, are suitable candidates for primary total hip replacement using the devices specified in this protocol
  • Individuals with non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, and posttraumatic arthritis
  • Individuals who are willing and able to provide informed patient consent for participation in the study
  • Individuals who are willing and able to return for follow-up as specified by the study protocol; and
  • Individuals who are willing and able to complete the Subject Hip Outcomes questionnaire as specified by the study protocol

Who cannot take part

  • Subject has participated in an IDE/IND clinical investigation, other than the COC28/COC36 IDE or PAS for their contralateral hip, with an investigational product in the last three months
  • Evidence of active infections that may spread to other areas of the body (e.g.,osteomyelitis, pyogenic infection of the hip joint, overt infection, urinary tract infection, etc.)
  • The presence of any known neoplastic (tumor-causing) or metastatic (spread of cancerous cells) disease
  • Significant neurologic or musculoskeletal disorders or diseases that may adversely affect gait, weight bearing or postoperative recovery (e.g., muscular dystrophy, multiple sclerosis)
  • Presence of highly communicable disease(s) that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.)
  • Any condition that may interfere with postoperative recovery (e.g., Paget's disease, Charcot's disease)
  • Use in patients with known allergies to the implant materials
  • Inflammatory degenerative joint disease (like rheumatoid arthritis)
  • Subject is a known drug or alcohol abuser or has a psychological disorder that could affect their ability to comply with protocol procedures and/or subject-completed questionnaires
  • The Subject has a medical condition with less than 2 years of life expectancy
  • Skeletally immature patients (tibial and femoral epiphyses not closed)
  • Inadequate bone stock to support the device (e.g., severe osteopenia orosteoporosis)
  • Poor skin coverage around the hip joint
  • Marked atrophy (muscle and/or tissue loss) or deformity in the upper femur such as a birth defect affecting the leg bones
  • Subject is currently involved in a personal injury litigation, medical-legal or worker's compensation claims
  • The Subject is a woman who is pregnant or lactating

Where in United States

Also in 1 other country, 4 sites

  • New England Baptist HospitalBoston, United StatesNo longer taking part
  • Tufts New England Medical CenterBoston, United StatesNo longer taking part
  • Orthopedic OneColumbus, United StatesNo longer taking part
  • Colorado Joint ReplacementDenver, United StatesNo longer taking part
  • Samuel Wellman, MD / Duke University Medical CenterDurham, United StatesNo longer taking part
  • Arthroplasty FoundationLouisville, United StatesNo longer taking part
  • UPennPhiladelphia, United StatesNo longer taking part
  • Joint Surgeons of SacrementoSacramento, United StatesNo longer taking part
  • Florida Orthopaedic InstituteTampa, United StatesNo longer taking part

About the trial

What the trial wants to find out

This study is intended to gather short (Pre-operative to 4-years) and mid-term (5-years) information regarding the performance and safety of the commercially available 36mm CERAMAX® Ceramic on Ceramic Total Hip System from a cohort of new study subjects that were not previously involved in the IDE study for this device.

The group in the trial

  • CERAMAX COC 36mm Acetabular CupOther group

    The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.

    Treatment: COC 36mm

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
36mm CERAMAX® Ceramic Hip System PMA PAS STUDY: Short to Mid-Term Follow-up , New Study Subjects (Ceramic Hip System, Subjects Receive CERAMAX 36mm Ceramic Acetabular Bearing Insert That Articulates With a Ceramic Femoral Head for THA)
Record updated
16 July 2025